Search Results for "prophylaxis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for prophylaxis. Results 91 to 100 of 194 total matches.
Low-Dose Colchicine for Coronary Artery Disease
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
) is FDA-approved for prophylaxis
and treatment of gout flares and for treatment of
familial ...
The centuries-old anti-inflammatory drug colchicine
(Colcrys, and others) is FDA-approved for prophylaxis
and treatment of gout flares and for treatment of
familial Mediterranean fever. It is also used off-label
to treat pericarditis, and in recent years has been
investigated for reduction of cardiovascular risk in
patients with coronary artery disease (CAD).
In Brief: New Polio Vaccination Guidance for Travelers
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014 (Issue 1450)
on an International Certificate of Vaccination
or Prophylaxis (“yellow card”). Children and adults
who ...
Wild poliovirus has circulated during the previous 12 months in Cameroon, Equatorial Guinea, Ethiopia, Iraq, Israel (also the West Bank and Gaza), Somalia, and Syria, as well as in those countries where polio is still endemic (Afghanistan, Nigeria, and Pakistan). The World Health Organization (WHO) has declared a public health emergency related to the possible spread of polio from affected countries. In response, the Centers for Disease Control and Prevention (CDC) has issued interim guidance for US residents planning travel to and from these countries.Vaccine Recommendations – All travelers...
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
A and B viruses,
have been the drugs of choice for treatment and
prophylaxis of influenza for many years ...
The FDA has approved baloxavir marboxil (Xofluza –
Shionogi/Genentech), the first polymerase acidic (PA)
endonuclease inhibitor, for single-dose, oral treatment
of acute uncomplicated influenza in patients ≥12 years
old. Baloxavir is the first drug with a new mechanism
of action to be approved for treatment of influenza in
almost 20 years.
Update: Influenza Resistance to Amantadine and Rimantadine
The Medical Letter on Drugs and Therapeutics • Jan 30, 2006 (Issue 1227)
Influenza Resistance to Amantadine and
Rimantadine
Our article on Antiviral Drugs for Prophylaxis ...
Our article on Antiviral Drugs for Prophylaxis and Treatment of Influenza (Med Lett Drugs Ther 2005;47:93) mentioned possible use of amantadine (Symmetrel, and others) and rimantadine (Flumadine, and others), but warned that the incidence of resistance has increased substantially. The CDC recently issued a Health Alert (www.cdc.gov) saying that current evidence indicates that a high proportion of circulating influenza A viruses in the US are now resistant to amantadine and rimantadine and they should not be used for this indication, at least this year. Click here to go to this update...
Montelukast for Persistent Asthma
The Medical Letter on Drugs and Therapeutics • Jul 17, 1998 (Issue 1031)
receptor antagonist, has been approved by the US Food and Drug Administration (FDA) for oral prophylaxis ...
Montelukast sodium (Singulair - Merck), a leukotriene receptor antagonist, has been approved by the US Food and Drug Administration (FDA) for oral prophylaxis and chronic treatment of asthma in adults and children at least 6 years old. It is the third 'leukotriene modifier' to become available in the USA; zafirlukast (Accolate - Medical Letter, 38:111, 1996) and zileuton (Zyflo - Medical Letter, 39:18, 1997) were marketed previously. Neither zafirlukast nor zileuton has been approved by the FDA for use in children less than 12 years old. Leukotriene modifiers are not recommended for...
Which Beta-Blocker?
The Medical Letter on Drugs and Therapeutics • Feb 05, 2001 (Issue 1097)
, migraine
prophylaxis
6
Sotalol --- --- no no low Ventricular
Betapace (Berlex) and others; arrhythmias ...
Some classes of drugs include so many agents that hospital formulary committees, managed care organizations and individual practitioners may find it difficult to choose among them. Fifteen beta-adrenergic receptor antagonists (beta-blockers) are now marketed for systemic use in the USA. One or more have been approved by the FDA for use in hypertension and eight other indications.
In Brief: Two Doses of Jynneos for Mpox (online only)
The Medical Letter on Drugs and Therapeutics • Jun 02, 2023 (Issue 5065)
or a prescription for
preexposure HIV prophylaxis) to have received one or two doses of Jynneos vaccine ...
The CDC is recommending that persons at high
risk of mpox (see Table 1) receive two doses of
the Jynneos vaccine. The recommendation follows
reports of a recent cluster of mpox cases in the US
and warnings about the risk of a renewed outbreak
during the spring and summer as people gather
for festivals and other events. The CDC does not
recommend routine immunization against mpox for
the general population.
Med Lett Drugs Ther. 2023 Jun 2;65(5065):1-2 doi:10.58347/tml.2023.5065a | Show Introduction Hide Introduction
Prevention and Treatment of Pertussis
The Medical Letter on Drugs and Therapeutics • Sep 17, 2012 (Issue 1399)
antimicrobial agents for the treatment
and postexposure prophylaxis of pertussis: 2005 CDC
guidelines. MMWR ...
The CDC has reported that many states are experiencing
a higher-than-usual incidence of pertussis this
year. The highest incidence has been in infants, but
the disease has also occurred in older children, adolescents,
and adults. Thirteen pertussis-related
deaths were reported through August 24; the majority
of these were in infants <3 months old.
Probiotics Revisited
The Medical Letter on Drugs and Therapeutics • Jan 07, 2013 (Issue 1407)
Products
gests that probiotic prophylaxis results in a large reduction
in Clostridium difficile ...
Probiotics are live, nonpathogenic microorganisms
(usually bacteria or yeasts) marketed as dietary supplements.
They have not been approved by the FDA for
any indication. Since our last article on this subject,
some new data have become available.
Belotero Balance for Wrinkles and Folds
The Medical Letter on Drugs and Therapeutics • Oct 28, 2013 (Issue 1428)
prescribe antiviral prophylaxis with
valacyclovir (Valtrex, and generics) before injection
and again 12 ...
Belotero Balance (Merz), an injectable hyaluronic acid
dermal filler, has been approved by the FDA for temporary
correction of moderate-to-severe facial wrinkles
and folds. Several other hyaluronic acid products are
also available for this indication (e.g., Restylane,
Perlane, Juvéderm). They have supplanted bovine collagen
products, which persist for a shorter time and
cause more allergic reactions.